Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vafidemstat in Borderline Personality Disorder
NCT04932291Phase 2Completed
- Sponsor
- Oryzon Genomics
- Start
- Mar 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of vafidemstat in borderline personality disorder (BPD), sponsored by Oryzon Genomics. Started Mar 2021; status: completed.
02
Drugs
vafidemstat
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT04932291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932291.